



Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

2/12/2024

- Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements
- Seamless integration with Spotfire® for powerful visual analytics enabling flexibility, easy customization and scalability
- Fosters cross-functional collaboration and improves overall efficiency in clinical research and development

WALTHAM, Mass.--(BUSINESS WIRE)-- Today, **Revvity, Inc.** (NYSE: RVTY) announced that its software and informatics division, **Revvity Signals**, is unveiling the **Signals Clinical™ solution**, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This state-of-the-art solution, when integrated with enterprise-class **Spotfire** visual analytics, has the potential to redefine how the pharmaceutical, biotechnology, and contract research industries approach clinical trial data, offering an unprecedented level of access and insight to drive forward clinical development and therapeutic innovations.

Kevin Willoe, SVP and general manager of Revvity Signals Software, Inc., emphasized the transformative potential of Signals Clinical, stating, "In the high-stakes realms of pharma, biotech, and contract research, the ability to swiftly and safely bring new treatments to market is paramount. Signals Clinical is our answer to the industry's urgent need for a solution that not only is designed to protect patient safety but also empowers data-driven decision-making with near real-time analytics. By integrating this platform with advanced data visualization tools, we're enabling our customers to navigate the complexities of clinical development with greater ease and efficiency, thereby accelerating the delivery of new drugs to patients."

Centralizing Clinical Data for Accelerated Decisions

Signals Clinical centralizes all clinical development data in one location and enables self-service access to clinical trial data, providing users with a complete picture of patient safety, treatment efficacy, and trial progress. This centralization enables rapid, actionable insights, facilitating faster and more informed clinical decisions, and significantly accelerating the time-to-market for essential therapeutics.

Empowering Life Sciences with Advanced Analytics

Signals Clinical, when combined with Spotfire not only streamlines the data preparation process but also enhances the delivery of strategic analyses, such as safety, efficacy and cross-study analysis. By reducing the time and resources spent on manual data handling, Signals Clinical allows organizations to focus on delivering critical clinical trial insights and fostering cross-functional collaboration.

Leading with FAIR Practices for Collaborative Data Management

Championing **FAIR principles**, the platform streamlines data preparation, reducing effort and maximizing value. It offers customizable workflows for data management, clinical review, and study monitoring, along with integrated collaboration tools. These features allow queries to be documented and referenced by study managers, enhancing collaboration and boosting overall team efficiency for clinical researchers.

Revvity Signals Software will present its Signals Clinical platform for the first time at the 15th Annual SCOPE conference (Booth #236), February 11-14, in Orlando, Florida.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than \$2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our **Newsroom**, **LinkedIn**, **X**, **YouTube**, **Facebook** and **Instagram**.

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Relations:

Chet Murray

(781) 663-5719

chet.murray@revvity.com

Source: Revvity